Literature DB >> 28294045

Dendrimers Effects on the Immune System: Insights into Toxicity and Therapeutic Utility.

Marina A Dobrovolskaia1.   

Abstract

BACKGROUND: Dendrimers are hyperbranched polymeric nanomaterials increasingly used in research, industrial and biomedical applications. Establishing safety profile of these particles includes an understanding of their interactions with blood components and the immune system.
METHOD: Herein I review the literature demonstrating how tuning dendrimer physicochemical properties influences their interaction with erythrocytes, platelets, plasma proteins, complement and coagulation systems. Dendrimer immunogenicity, adjuvanticity, allergenicity, anti-inflammatory, immunosuppressive and antibacterial properties are also discussed.
CONCLUSION: Dendrimers hemato- and immune- compatibility are determined by particle size, architecture, type and density of surface functional groups. Case studies from the literature are discussed to support this conclusion. The review also highlights questions which require more thorough investigation to fill the gaps in our understanding of immunological properties of dendrimers. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Dendrimers; adjuvant; antibody.; antigen; nanoparticles; vaccines

Mesh:

Substances:

Year:  2017        PMID: 28294045     DOI: 10.2174/1381612823666170309151958

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  13 in total

1.  Self-assembly of four generations of RNA dendrimers for drug shielding with controllable layer-by-layer release.

Authors:  Xin Li; Mario Vieweger; Peixuan Guo
Journal:  Nanoscale       Date:  2020-07-30       Impact factor: 7.790

Review 2.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

3.  Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.

Authors:  Ingrid S Ganda; Qian Zhong; Mirabela Hali; Ricardo L C Albuquerque; Francine F Padilha; Sandro R P da Rocha; Judith A Whittum-Hudson
Journal:  Int J Pharm       Date:  2017-05-22       Impact factor: 5.875

4.  Targeting Mitochondria in Tumor-Associated Macrophages using a Dendrimer-Conjugated TSPO Ligand that Stimulates Antitumor Signaling in Glioblastoma.

Authors:  Anjali Sharma; Kevin Liaw; Rishi Sharma; Ajit G Thomas; Barbara S Slusher; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Biomacromolecules       Date:  2020-08-31       Impact factor: 6.988

5.  Systemic dendrimer delivery of triptolide to tumor-associated macrophages improves anti-tumor efficacy and reduces systemic toxicity in glioblastoma.

Authors:  Kevin Liaw; Rishi Sharma; Anjali Sharma; Sebastian Salazar; Santiago Appiani La Rosa; Rangaramanujam M Kannan
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

6.  Dendrimer size effects on the selective brain tumor targeting in orthotopic tumor models upon systemic administration.

Authors:  Kevin Liaw; Fan Zhang; Antonella Mangraviti; Sujatha Kannan; Betty Tyler; Rangaramanujam M Kannan
Journal:  Bioeng Transl Med       Date:  2020-04-14

7.  Targeting Mitochondrial Dysfunction and Oxidative Stress in Activated Microglia using Dendrimer-Based Therapeutics.

Authors:  Anjali Sharma; Kevin Liaw; Rishi Sharma; Zhi Zhang; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Theranostics       Date:  2018-11-05       Impact factor: 11.556

8.  Preferential and Increased Uptake of Hydroxyl-Terminated PAMAM Dendrimers by Activated Microglia in Rabbit Brain Mixed Glial Culture.

Authors:  Yossef Alnasser; Siva P Kambhampati; Elizabeth Nance; Labchan Rajbhandari; Shiva Shrestha; Arun Venkatesan; Rangaramanujam M Kannan; Sujatha Kannan
Journal:  Molecules       Date:  2018-04-27       Impact factor: 4.411

9.  Systemic dendrimer-drug nanomedicines for long-term treatment of mild-moderate cerebral palsy in a rabbit model.

Authors:  Zhi Zhang; Yi-An Lin; Soo-Young Kim; Lilly Su; Jinhuan Liu; Rangaramanujam M Kannan; Sujatha Kannan
Journal:  J Neuroinflammation       Date:  2020-10-25       Impact factor: 9.587

Review 10.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.